Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617213 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01617213 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 1 participants.
The verdict
NCT01617213, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Interventions
- DRUG Melphalan
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01617213
The ClinicalTrials.gov registry entry for NCT01617213 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melphalan is the first listed.
NCT01617213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01617213 about?
NCT01617213 is a clinical study titled "Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma". This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
What is the current status of trial NCT01617213?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-04.
What interventions are being tested in trial NCT01617213?
The interventions under investigation include: Melphalan (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01617213?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.